Lincoln Pharmaceuticals Q4 FY26 Results: Revenue, PAT, Net Profit and Key Highlights

Lincoln Pharmaceuticals Q4 FY26 results were declared on May 28, 2026. The company reported net profit of Rs 11.6 crore for the quarter ended March 31, 2026, -4.9% YoY. Revenue from operations was Rs 190 crore, +7.3% YoY. Results are on a standalone basis. Lincoln Pharmaceuticals is a Pharmaceutical Formulations and OTC Products company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Lincoln Pharmaceuticals Q4 FY26 Financial Highlights

Metric	Q4 FY26	Q4 FY25	YoY Change
Revenue from Operations (Rs Cr)	190	177	+7.3%
Net Profit (PAT) (Rs Cr)	11.6	12.2	-4.9%
Reporting Basis	Standalone

Note: Q4 FY26 PAT Rs 11.6 Cr (-4.9% YoY from Rs 12.2 Cr). Revenue Rs 190 Cr (+7.3% YoY). Marginal PAT decline from higher operating costs. Always verify from BSE/NSE audited filings before investment decisions.

Lincoln Pharmaceuticals Q4 FY26 Performance Analysis

The Lincoln Pharmaceuticals Q4 FY26 results reflect performance in the January to March 2026 quarter. Revenue grew to Rs 190 crore, +7.3% YoY. Net profit of Rs 11.6 crore reflects the company’s operational efficiency. Lincoln Pharmaceuticals operates in the Pharmaceutical Formulations and OTC Products sector.

India’s macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth above 6.5%, government capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. The Pharmaceutical Formulations and OTC Products sector benefited from these structural tailwinds during the January to March 2026 quarter.

Key Business Factors in Q4 FY26

Revenue and Volume Performance

Revenue from operations grew to Rs 190 crore, +7.3% YoY in Lincoln Pharmaceuticals Q4 FY26. The Pharmaceutical Formulations and OTC Products sector benefited from India’s domestic demand recovery and infrastructure push in FY26.

Profitability and Margin Trajectory

Q4 FY26 net profit of Rs 11.6 crore demonstrates strong profitability.

Sector and Macro Backdrop

India’s macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. These factors supported business investment and consumer spending. The Pharmaceutical Formulations and OTC Products sector benefited from these structural tailwinds during the quarter ended March 31, 2026.

Dividend Details

No dividend was declared for Q4 FY26. The company channelled resources towards operational growth in Q4 FY26.

FY27 Outlook

Following the Lincoln Pharmaceuticals Q4 FY26 results, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and order book health. Execution against strategic priorities in FY27 will be critical for sustained performance. India’s GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Lincoln Pharmaceuticals in FY27.

Lincoln Pharmaceuticals Stock Performance

Download the Univest iOS App or Univest Android App to track live price and daily stock recommendations.

Shares of Lincoln Pharmaceuticals are listed on NSE and BSE. Following the Q4 FY26 results on May 28, 2026, investors should monitor post-results price action and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.

Key Risks

Revenue and Demand Risk

Any deceleration in India’s GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Lincoln Pharmaceuticals’s products and services in the Pharmaceutical Formulations and OTC Products sector in FY27.

Margin and Cost Volatility

Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks. Any cost escalation without corresponding pricing power could compress profitability from Q4 FY26 levels.

Regulatory and Competitive Risk

Changes in regulatory frameworks, competitive pressure from domestic and global peers, and customer concentration risks are key watchpoints for Lincoln Pharmaceuticals investors in FY27.

Conclusion

Lincoln Pharmaceuticals Q4 FY26 results declared on May 28, 2026 showed net profit of Rs 11.6 crore, -4.9% YoY. The results reflect the company’s execution capability heading into FY27. Investors should monitor management guidance and sector trends before making investment decisions.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE/NSE audited filings.

Frequently Asked Questions on Lincoln Pharmaceuticals Q4 FY26 Results

What is Lincoln Pharmaceuticals Q4 FY26 net profit?

Ans. Lincoln Pharmaceuticals Q4 FY26 net profit was Rs 11.6 crore, -4.9% YoY. Results declared May 28, 2026.

What is Lincoln Pharmaceuticals Q4 FY26 revenue?

Ans. Lincoln Pharmaceuticals Q4 FY26 revenue was Rs 190 crore, +7.3% YoY.

When were Lincoln Pharmaceuticals Q4 FY26 results declared?

Ans. Lincoln Pharmaceuticals Q4 FY26 results were declared on May 28, 2026 at the board meeting approving audited financial statements for the quarter and year ended March 31, 2026.

What dividend did Lincoln Pharmaceuticals declare for FY26?

Ans. No dividend was declared for Q4 FY26. Verify from BSE/NSE filings for record date and payout schedule.

What is the FY27 outlook for Lincoln Pharmaceuticals?

Ans. Following Lincoln Pharmaceuticals Q4 FY26 results, management guidance on revenue growth, margin improvement, and capital allocation shapes FY27 expectations. Consult a SEBI-registered advisor before investing.

Is Lincoln Pharmaceuticals a good buy after Q4 FY26 results?

Ans. Investment decisions in Lincoln Pharmaceuticals require assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This article is for educational purposes only. Consult a SEBI-registered financial advisor.

What sector does Lincoln Pharmaceuticals operate in?

Ans. Lincoln Pharmaceuticals operates in the Pharmaceutical Formulations and OTC Products sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 28, 2026.